ERBB2 and pancreatic ductal adenocarcinoma: Previously, we have shown the efficacy of bsAb, such as [HER2xCD3] and [(HER2)2xVγ9], which selectively target CD3- and/or Vγ9-expressing T cells to HER2-expressing pancreatic ductal adenocarcinoma (PDAC) cells.